Lyell Immunopharma, Inc.LYEL

Market cap

$9.5B

P/E ratio

	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Cash and cash equivalents	294	124	146	106
Marketable securities	321	517	401	265
Prepaid expenses and other current assets	11	11	8	9
Total current assets	626	651	555	380
Restricted cash	0	0	0	2
Marketable Securities, Noncurrent	284	70	17	13
Other investments	47	45	32	19
Property and equipment, net	120	123	103	48
Operating lease right-of-use assets	47	43	40	25
Other non-current assets	3	5	4	5
Total assets	1,127	938	750	491
Accounts payable	3	4	5	5
Accrued Liabilities and Other Liabilities	29	29	28	40
Success payment liabilities	9	4	2	0
Contingent consideration payable	-	-	-	8
Total current liabilities	47	37	35	54
Operating Lease, Liability, Noncurrent	67	63	57	51
Other non-current liabilities	5	4	4	3
Total liabilities	198	104	95	108
Common Stock, Value, Issued	0	0	0	0
Additional paid-in capital	1,516	1,608	1,657	1,728
Accumulated other comprehensive income (loss)	-2	-8	-0	0
Accumulated deficit	-584	-767	-1,002	-1,345
Total stockholders’ equity	930	833	655	383
Total liabilities and stockholders’ equity	1,127	938	750	491